Phase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer

Trial ID #	NCT00408590
Phase	I
Drug Class	Oncolytic Viruses
Drug Name	MV-NIS
Alternate Drug Names	oncolytic measles virus encoding thyroidal sodium iodide symporter
Drugs in Trial	MV-NIS
Eligible Participant	Platinum resistant or refractory ovarian cancer
Patients Enrolled	16; median 4 prior therapies (1-8)
Therapy Setting	Recurrence
Study Design	Open-Label, Non-randomized
Endpoints	ORR, OS, evaluated per RECIST
Efficacy	DCR: 81.3% (13SD, n=16) Median duration of SD: 2.2 months (1.8-9.2) 2 patients had decreasing CA125 levels OS: 26.5 months
Clinically Significant Adverse Events	Serious AE: None Grade 3-4 AE: None
Conclusion	Intraperitoneal administration of MV-NIS is safe with early evidence of antitumor activity and treatment with MV-NIS augments endogenous immunity against tumor antigens
Reference	Galanis E et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res (2015) 75(1):22-30 https://www.ncbi.nlm.nih.gov/pubmed/25398436